Loading...
•
Jun 30, 2021
Utah Medical Q2 2021 Earnings Report
Second quarter results for 2021 showed excellent recovery from the low point during the COVID-19 pandemic.
Key Takeaways
Utah Medical Products reported a significant increase in revenue, gross profit, and operating income compared to Q2 2020, which was the low point of performance during the COVID-19 pandemic. The company's financial results confirm that UTMD may be back on track after surviving a depression in its business in 2020.
Total consolidated sales were $12.604 million, a 43.4% increase compared to Q2 2020.
U.S. domestic sales increased by 46% and sales outside the U.S. increased by 40%.
Net income was $3.426 million, a 161% increase compared to Q2 2020.
Earnings per share were $0.937, a 161.3% increase compared to Q2 2020.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management expects that adjusted consolidated EBITDA of $25 million is likely achievable for the full year 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...